Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Provides 3rd Quarter 2022 Business and Financial Update; Dosing of KIO-301 in Phase 1 Trial for Retinitis Pigmentosa to Begin Before Year's End

Salt Lake City, Utah--(Newsfile Corp. - November 9, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today is providing a business update and reporting financial results

Related Keywords

Kiora ,New South Wales ,Australia ,Austria ,Salt Lake City ,Utah ,United States ,Australian ,Austrian ,Francina Agosti ,Eric Daniels ,Brianm Strem ,Utah Newsfile Corp ,Kiora Pharmaceuticals ,Linkedin ,Twitter ,Kiora Pharmaceuticals Inc ,Nasdaq ,Chief Executive Officer ,Retinitis Pigmentosa ,Persistent Corneal Epithelial Defects ,Rheumatoid Arthritis ,Persistent Corneal Epithelial ,Melissa Tosca ,Executive Vice President ,Ocular Presentation ,Dihydroorotate Dehydrogenase ,Private Securities Litigation Reform Act ,Annual Report ,Pharmaceuticals ,Rovides ,Quarter ,022 ,Business ,Financial ,Update ,Closing ,Hase ,Trial ,Retinitis ,Pigmentosa ,Begin ,Before ,Ear ,